Evidence map›Paper›PMID 39974071›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Modeling diagnostic code dropout of schizophrenia in electronic health records improves phenotypic data quality and cross-ancestry transferability of polygenic scores.

David Burstein, Simone Tomasi, Sanan Venkatesh, VA Million Veteran Program, Mina Rizk, Panos Roussos, Georgios Voloudakis

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David BursteinCenter for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx, NY, USA.
Simone TomasiCenter for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx, NY, USA.
Sanan VenkateshCenter for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx, NY, USA.
VA Million Veteran Program
Mina RizkDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Panos RoussosCenter for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx, NY, USA.
Georgios VoloudakisCenter for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx, NY, USA.ORCID 0000-0002-5729-632X

Funding

Understanding the molecular mechanisms that contribute to neuropsychiatric symptoms in Alzheimer DiseaseR01AG067025 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FINKBEINER, STEVEN M, HAROUTUNIAN, VAHRAM · 2019 to 2023
$11.8M
Understanding the protective and neuroinflammatory role of human brain immune cells in Alzheimer DiseaseR01AG065582 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM, ROUSSOS, PANAGIOTIS · 2020 to 2024
$9.9M
The adaptive-innate immune interactome across multiple tissues in Alzheimer's diseaseR01AG082185 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI VAHRAM HAROUTUNIAN, Donghoon Lee · 2023 to 2026
$9.0M
Multiethnic genomic epigenomic and transcriptomic fine-mapping and functional validation analysis of schizophrenia and bipolar disorder risk lociR01MH125246 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROUSSOS, PANAGIOTIS · 2021 to 2025
$5.0M
Identifying genetically driven gene dysregulation in Alzheimer's disease and related dementias using statistical data integrationR01AG078657 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Georgios Voloudakis · 2023 to 2026
$2.7M
Characterizing and targeting subphenotypes of schizophrenia and bipolar disorder via individually imputed tissue and cell-type specific transcriptomesK08MH122911 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI VOLOUDAKIS, GEORGIOS · 2020 to 2023
$770k
BLRD VA I01 BX004189BLRD VA I01 BX006500NIA NIH HHS R01 AG065582NIA NIH HHS R01 AG067025NIA NIH HHS R01 AG078657NIA NIH HHS R01 AG082185NIMH NIH HHS K08 MH122911NIMH NIH HHS R01 MH125246
6 · The paper itself

Abstract

Importance: Researchers commonly use counts of diagnostic codes from EHR-linked biobanks to infer phenotypic status. However, these approaches overlook temporal changes in EHR data, such as the discontinuation or "dropout" of diagnostic codes, which may exacerbate disparities in genomics research, as EHR data quality can be confounded with demographic attributes. Objective: To address this, we propose modeling diagnostic code dropout in EHR data to inform phenotyping for schizophrenia in genomic analyses. Design: We develop and test our diagnostic dropout model by analyzing EHR data from individuals with prior schizophrenia diagnoses. We further validate model performance on a subset of patients whose diagnoses were attained through chart review. Using PRS-CS and existing GWAS summary statistics, we first extrapolate polygenic weights. Then, we apply our dropout model's outputs to construct a data-driven filter defining our target cohort for measuring polygenic score performance. Setting: Our analysis utilizes EHR and genomic data from the Million Veteran Program. Participants: To model diagnostic dropout in schizophrenia, we leverage data from 12,739 patients with a history of schizophrenia, after excluding outliers. For polygenic score analyses, we incorporate data from a potential pool of 8,385 European ancestry and 6,806 African ancestry patients with a history of schizophrenia. Main outcomes and measures: We compare the performance of our diagnostic dropout model with alternative methodologies both in predicting diagnostic dropout on a holdout set, as well as on chart review labeled data. Using the top differential diagnosis predictors in our model, we select relevant cases by filtering out patients with a prior history of mood or anxiety disorders. We then test the impact of applying different filters for measuring polygenic score performance. Results: When evaluated on chart review-labeled data, our model improves the area under the precision-recall curve (AUPRC) by 9.6% compared to competing methods. By applying our data-driven filter for schizophrenia, we achieve a 62% increase in the association effect size when transferring a European polygenic score to an African ancestry target cohort. Conclusions and Relevance: These findings highlight the potential of modeling diagnostic code dropout to enhance the phenotypic quality of EHR-linked biobank data, advancing more equitable and accurate genomics research across diverse populations.

Identifiers

PMID39974071
PMCPMC11838988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.